%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Merck & Company Inc(MRK) Stock Analysis | Healthcare
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.What is Merck & Company Inc?
operates as a healthcare company worldwide.
The brief on Merck & Company Inc
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
What is Merck & Company Inc?
operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 359.22B, and a P/E ratio of 115.6x.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (51)Similar stocks to compare
A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 10320,176 shares $38.3M | 0 |
| 9-12months | 18,614 shares $720k | 0 |
Openbook research
Articles mentioning MRK
- Read
Is Summit Therapeutics a Good Long-Term Investment? SMMT Growth, Profitability and Risks
AstraZeneca's USD 2bn stake removes Summit's financing overhang but buys no licence on ivonescimab. Why the shares gave back most of a 22% pop.
- Read
How Merck (MRK) Makes Its Money: Oncology and Vaccine Fundamentals
A Merck stock analysis of where MRK earns its revenue across oncology, vaccines and animal health, and what the 2028 Keytruda patent expiry changes.
- Read
Moderna After the Cancer Vaccine Data: What Has to Be True
A first-in-class Phase 3 win added about USD 32bn to Moderna in three sessions. The cash line, guided lower by year end, is the factor nobody discussed.
- Read
Moderna (MRNA) Stock Analysis: The Melanoma Data and the Numbers
A Moderna stock analysis after the 177 percent move: what the INTerpath-001 melanoma readout disclosed, Q2 2026 revenue and losses, and the cash runway.